Q2 2026 saw strong ARCALYST sales growth and increased revenue guidance, supported by robust cash reserves and expanding prescriber base. Pipeline progress includes KPL-387 advancing to Phase 3, and strategic partnerships are driving global expansion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.